Business Wire

Extenda Retail Chooses Styra DAS to Operationalize OPA at Global Scale

14.9.2021 15:00:00 CEST | Business Wire | Press Release

Share

Styra, Inc., the founders of Open Policy Agent (OPA) and leaders in cloud-native authorization, today announced that Extenda Retail, the Nordic-based software provider for leading retailers, has adopted OPA and Styra Declarative Authorization Service (DAS) as a unified approach to authorization and access control for their customer retail platform.

Extenda Retail’s mission is to help retailers grow their business while also improving customer experience. As more and more of their customers moved to the cloud, Extenda Retail developed the Hii Retail platform, which translates to “High Intensity Intelligent Retail.” Hii Retail provides key services that improve global retailers’ flexibility, agility and speed-to-market, from concept to store roll-out.

However, as they moved to the cloud, Extenda Retail’s engineering team realized that they had a problem at the authorization and policy level. They found that legacy, centralized authorization failed to scale or meet their compliance needs, and that rearchitecting authorization for cloud-native was more complex than anticipated. The team needed a flexible authorization solution with a consistent way of writing policy to control access to their microservices-based applications at customers’ sites. Since customer sites are globally distributed, and have varying levels of Internet access, Extenda also needed a solution that made authorization decisions locally and immediately. To meet all these needs, the team turned to OPA and Styra DAS.

Decouple Policy with OPA

OPA allows teams to decouple policy logic from service proxies, so Extenda Retail developers didn’t need to hardcode rules into the app services, or the proxies themselves. In other words, their developers can read, write, analyze, version, distribute and in general manage access policy without making any changes to the app architecture itself. This decoupled policy reduces risk of introducing bugs and errors into the app, and greatly simplifies authorization policy changes.

Having a flexible consistent way of writing policy and authorization enables the Extenda Retail team to focus on innovative features for their core products, rather than writing policy directly into a specific set of services and proxies. However, the company knew that if they wanted to scale OPA at both the cloud and local level, they needed a solution to help manage all of their instances of OPA, across all the various apps within the Hii Retail platform, and help ensure all their policy decisions were in compliance with regulations.

Manage OPA and Prove Compliance with Styra DAS

Styra DAS is the unified control point for OPA, that allows the Extenda Retail team to create and collaborate about policy, make policy changes in a single place, and then push those changes to the relevant instances of OPA locally in the stores. Styra DAS eliminates the need for manual updates or custom policy distribution scripts, which leads to less risk of accidental error.

“Authorization is hard to get right,” said Shayne Clausson, VP of Engineering at Extenda Retail. “We don’t want teams to have to focus on that. We want them to be able to get to the interesting part of their services. By using Open Policy Agent and Styra DAS to decouple policy from the underlying services, our team can easily ensure we are meeting compliance regulations so they have more time to focus on innovation.”

Extenda Retail operates in a heavily regulated environment. Without the use of Styra DAS, the team would be forced to manually track policy decisions for each instance of OPA. When compliance is critical, this method is risky. Styra DAS mitigates this risk with real-time monitoring and detailed logging of OPA decisions, so the Extenda Retail team can prove compliance both internally and externally.

“We built Styra DAS for exactly these kinds of deployments,” said Tim Hinrichs, co-founder and Chief Technology Officer of Styra. “When millions, or even billions, of OPA decisions are required, and thousands of OPA instances are deployed, Styra DAS is the only way to manage all those OPA instances and prove compliance based on those decisions. Styra DAS is the only way to operationalize OPA at scale.”

Read the full Extenda Retail and Styra case study here.

Learn more about securing your cloud-native solutions with Styra.

About Styra

Styra, the founders of Open Policy Agent (OPA), provides open source and commercial solutions that enable enterprises to define, enforce and monitor authorization policy across their cloud-native applications, as well as the infrastructure they run on. Styra policy-as-code solutions let developers, DevOps and security teams mitigate risks, reduce human error and accelerate application development.

About Extenda Retail

Extenda Retail inspires retailers to go further through frictionless and game-changing software, which helps retailers grow their business and optimise their customers' experience. The extensive portfolio of solutions includes Hii Retail cloud applications, POS (point-of-sale) & Checkout, WMS, Customer Intelligence & Loyalty, and Pharmacy software. With over 40 years as an industry-leader in retail software development, hundreds of retail chains with a presence in 37 countries across the globe utilise solutions by Extenda Retail. Learn more at www.extendaretail.com or follow on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Victoria Johnson
Walker Sands for Styra
victoria.johnson@walkersands.com
312-235-4317

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye